While patients in Canada, Europe, and Australia access life-saving therapies, Americans are left waiting, sometimes decades, due to the FDA’s rigid bottleneck. Bautista Vivanco, a Young Voices contributor and Research Associate at the Department of Health Policy Studies, where he analyzes FDA drug approvals, the budgets of health-related government programs, and global health indicators, joins WRFH to discuss.